Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: From benchwork to clinical application

EuroIntervention

Volumn 7, Issue 3, 2011, Pages 386-399

  Farooq, Vasim ^a   Onuma, Yoshinobu ^a   Radu, Maria ^a   Okamura, Takayuki ^a   Gomez Lara, Josep ^a   Brugaletta, Salvatore ^a   Gogas, Bill D ^a   Van Geuns, Robert Jan ^a   Regar, Evelyn ^a   Schultz, Carl ^a   Windecker, Stephan ^b   Lefèvre, Thierry ^c   Brueren, B R Guus ^d   Powers, Jennifer ^e   Perkins, Laura L ^e   Rapoza, Richard J ^e   Virmani, Renu ^f   García García, Hector M ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c Institut Jacques Cartier   (France)

^d CATHARINA HOSPITAL   (Netherlands)

^e ABBOTT VASCULAR   (United States)

^f CVPATH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; POLYLACTIC ACID;

ANGIOCARDIOGRAPHY; ARTICLE; BIODEGRADABLE IMPLANT; BLOOD FLOW; DRUG ELUTING STENT; DRUG RELEASE; HUMAN; IMPLANTATION; IN VITRO STUDY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PHANTOM; QUALITY CONTROL; STABLE ANGINA PECTORIS; THICKNESS; UNSTABLE ANGINA PECTORIS; VEIN;

ABSORBABLE IMPLANTS; AGED; ANGINA PECTORIS; ANGINA, UNSTABLE; ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; HUMANS; MALE; MODELS, ANIMAL; SWINE; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 80355137324     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7I3A64     Document Type: Article

References (21)

1. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907. (Pubitemid 351384734)
2. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006;18:70-74.
3. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
4. Onuma Y, Serruys PW, Ormiston JA, Regar E, Webster M, Thuesen L, Dudek D, Veldhof S, Rapoza RJ. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2010; in press.
5. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70:515-523. (Pubitemid 47597022)
6. Tanimoto S, Bruining N, van Domburg RT, Rotger D, Radeva P, Ligthart JM, Serruys PW. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol 2008;52:1616-1620.
7. Ormiston J, Webster M. Absorbable coronary stents. Lancet 2007;369:1839-1840. (Pubitemid 46829343)
8. Okamura T, Garg S, Gutierrez-Chico JL, Shin ES, Onuma Y, Garcia-Garcia HM, Rapoza RJ, Sudhir K, Regar E, Serruys PW. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010;5:932-938.
9. Onuma Y, Serruys PW, Perkins L, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers J, Rapoza RJ, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography (OCT) and histology at 1 month, at 2, 3 and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: An attempt to decipher the human OCT images in the ABSORB trial. Circulation 2010;122:2288-300.
10. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation 2010;122: 2301-12.
11. Costa MA, Angiolillo DJ, Tannenbaum M, Driesman M, Chu A, Patterson J, Kuehl W, Battaglia J, Dabbons S, Shamoon F, Flieshman B, Niederman A, Bass TA. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol 2008;101:1704-1711.
12. Gomez-Lara J, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston JA, Windecker S, Whitbourn R, Dudek D, Dorange C, Veldhof S, Rapoza R, Regar E, Garcia-Garcia HM, Serruys PW. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting Bioresorbable Vascular Scaffold as assessed by optical coherence tomography. EuroIntervention in press.
13. Okamura T, Onuma Y, Garcia-Garcia HM, Regar E, Wykrzykowska JJ, Koolen J, Thuesen L, Windecker S, Whitbourn R, McClean DR, Ormiston JA, Serruys PW. 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. JACC Cardiovasc Interv 2010;3:836-844.
14. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-278. (Pubitemid 40982311)
15. Lim SY, Jeong MH, Hong SJ, Lim do S, Moon JY, Hong YJ, Kim JH, Ahn Y, Kang JC. Inflammation and delayed endothelization with overlapping drug-eluting stents in a porcine model of instent restenosis. Circ J 2008;72:463-468.
16. Otsuka Y, Chronos NA, Apkarian RP, Robinson KA. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. J Invasive Cardiol 2007;19:71-76.
17. Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von Birgelen C. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention 2009;5:157-165.
18. Tahara S, Bezerra HG, Sirbu V, Kyono H, Musumeci G, Rosenthal N, Guagliumi G, Costa MA. Angiographic, IVUS and OCT evaluation of the long-term impact of coronary disease severity at the site of overlapping drug-eluting and bare metal stents: a substudy of the ODESSA trial. Heart 2010;96:1574-1578.
19. Costa JR, Jr., Sousa A, Moreira AC, Costa RA, Cano M, Maldonado G, Campos C, Carballo M, Pavanello R, Sousa JE. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry. JACC Cardiovasc Interv 2010;3:12-18.
20. Aoki J, Mintz GS, Weissman NJ, Mann JT, Cannon L, Greenberg J, Grube E, Masud AR, Koglin J, Mandinov L, Stone GW. Chronic arterial responses to overlapping paclitaxel-eluting stents: insights from serial intravascular ultrasound analyses in the TAXUS-V and -VI trials. JACC Cardiovasc Interv 2008; 1:161-167. (Pubitemid 351512279)
21. Guagliumi G, Musumeci G, Sirbu V, Bezerra HG, Suzuki N, Fiocca L, Matiashvili A, Lortkipanidze N, Trivisonno A, Valsecchi O, Biondi-Zoccai G, Costa MA. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2010;3:531-539.